EA
KALV

Emerald Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Emerald Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,264,023
Closed -$25.4M – 249
2026
Q1 		$25.4M Sell
1,264,023
-76,472
-6% -$1.23M 0.81% 55
2025
Q4 		$21.6M Sell
1,340,495
-10,759
-0.8% -$142K 0.67% 69
2025
Q3 		$16.5M Buy
1,351,254
+313,205
+30% +$4.33M 0.53% 78
2025
Q2 		$11.7M Buy
1,038,049
+139,859
+16% +$1.71M 0.43% 89
2025
Q1 		$10.4M Buy
898,190
+62,140
+7% +$634K 0.47% 81
2024
Q4 		$7.08M Buy
836,050
+62
+0% +$642 0.27% 103
2024
Q3 		$9.68M Buy
835,988
+192,091
+30% +$2.42M 0.37% 88
2024
Q2 		$7.59M Sell
643,897
-27,279
-4% -$318K 0.32% 101
2024
Q1 		$7.96M Buy
+671,176
New +$8.95M 0.32% 102
2021
Q4 		– Sell
-304,113
Closed -$5.31M – 287
2021
Q3 		$5.31M Sell
304,113
-70,520
-19% -$1.43M 0.19% 115
2021
Q2 		$8.98M Sell
374,633
-22,650
-6% -$593K 0.33% 105
2021
Q1 		$10.2M Buy
+397,283
New +$10.4M 0.37% 104

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Emerald Advisers's KALV Position: Q2 2026 in Review

Emerald Advisers sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,264,023 shares — an estimated $25.4M sold.

Emerald Advisers first reported a position in KALV in Q1 2021 and held it in 12 quarters. The position peaked at $25.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Emerald Advisers reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Emerald Advisers sold 1,264,023 KalVista Pharmaceuticals shares in Q2 2026, an estimated $25.4M.
  • Emerald Advisers first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Emerald Advisers's KalVista Pharmaceuticals position peaked at $25.4M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.